双免疫检查点阻断使MMR缺陷型Lynch综合征相关CNS WHO 3级脑膜瘤获持久完全缓解
本文报告一例Lynch综合征相关的复发性高级别脑膜瘤患者,肿瘤存在DNA错配修复缺陷。患者接受两种免疫治疗药物后改为单药治疗,肿瘤完全消失且停药后持续缓解。治疗前肿瘤组织分析显示大量活跃免疫细胞浸润,提示免疫微环境可能有利于免疫应答。
要点
- Lynch综合征相关高级别脑膜瘤可存在MMR缺陷,或对双免疫检查点阻断敏感。
- 双免疫治疗后单药维持可使肿瘤完全消失,停药后缓解持久。
- 治疗前肿瘤组织活跃免疫细胞浸润可能提示免疫应答有利环境。
核心结论
- MMR缺陷型Lynch综合征相关CNS WHO 3级脑膜瘤经双免疫检查点阻断后获持久完全缓解。
研究设计与样本
- 个案报告:一例Lynch综合征相关的复发性高级别脑膜瘤患者。
主要发现
- 患者接受两种免疫治疗药物后改为单药治疗,肿瘤完全消失且停药后持续缓解。
- 治疗前肿瘤组织分析发现大量活跃免疫细胞,提示免疫微环境可能有利于免疫应答。
临床怎么用
- 对复发高级别脑膜瘤可考虑评估Lynch综合征及MMR缺陷状态。
- 治疗前肿瘤免疫微环境分析可能有助于判断免疫治疗获益潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade meningiomas are rare brain tumors with limited treatment options when they return after surgery and radiotherapy. We describe a patient with a recurrent meningioma associated with Lynch syndrome and genetic changes affecting the tumor’s ability to repair its DNA. The patient received two immunotherapy drugs followed by treatment with one drug alone and achieved complete disappearance of the tumor, which persisted after treatment was stopped. We also analyzed the tumor tissue collected before immunotherapy and found many active immune cells, indicating an environment potentially favorable to an immune response. This case highlights the importance of studying both tumor genetics and its immune environment.
引用
- Maccari M, Marinelli E, Caccese M, et al. Durable complete response to dual immune checkpoint blockade in an MMR-deficient, Lynch syndrome-associated CNS WHO grade 3 meningioma. Neuro Oncol. 2026. PMID: 42820764. doi:10.1093/neuonc/noag239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。